cas2235-sup-0001-fS1.tifimage/tif2353KFig. S1. Flow cytometric analysis of cell cycle progression in Capan-1 cells treated with gemcitabine (100 ng/mL) for 12 or 24 h.
cas2235-sup-0002-fS2.tifimage/tif2248KFig. S2. Flow cytometric analysis of CD133 expression in Capan-1 cells treated with or without interferon-alpha (IFN-α). IFN-α treatment (5000 IU/mL) for 24 h decreased the ratio of CD133+ Capan-1 cells over time.
cas2235-sup-0003-fS3.tifimage/tif1610KFig. S3. Comparison of BrdU assay between CD133+ and CD133 Capan-1 cells treated with gemcitabine (GEM) (100 ng/mL) alone, interferon-alpha (IFN-α) (5000 U/mL) alone or GEM combined with IFN-α for 24 h.
cas2235-sup-0004-fS4.tifimage/tif768KFig. S4. (A) Body weight curves of nude mice were not significantly different among the three treatments, which were gemcitabine (GEM) (100 ng/mL) alone, interferon-alpha (IFN-α) (5000 U/mL) alone or GEM plus IFN-α. (B) Comparison of proportions of CD133+ cells in Capan-1 xenografts that were treated with GEM (100 ng/mL) alone, IFN-α (5000 U/mL) alone or GEM plus IFN-α at week 2 and 5.
cas2235-sup-0005-fS5.tifimage/tif4396KFig. S5. (A) Comparison of the number of spheres per well (cm3) for pancreatic cancer cell lines, Panc-1, Capan-1, MIA PaCa-2, PK45H and SW1990. The white and black bars indicate the spheres composed of 3–30 and >30 cells, respectively. (B) Immunohistochemical study of a Capan-1 tumor generated by transplantation into non-obese diabetic (NOD)/SCID mice. (i) HE staining and (ii, iii, iv) immunostaining performed to identify cytokeratin (CK) and CD133 expression, respectively.
cas2235-sup-0006-tS1.docWord document32KTable S1. Comparison of potential markers related to tumor-initiating cells in six pancreatic cancer cell lines.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.